Jim Cramer: Buy Rite Aid, Verizon, and These 2 Stocks
Jim Cramer made the following calls on September 27th, 2013. What do you think about his picks?
Rite Aid Corp. (NYSE:RAD): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 13, 2013. The stock’s 52-week high is $5.08, and its 52-week low is $0.95. Cramer called Rite Aid a real turn around, as the company has posted exceptional gains so far this year. Recently, though, Rite Aid was forced to pay $12 million as part of a settlement in an environmental lawsuit, which has negatively impacted shares.
Verizon Communications Inc. (NYSE:VZ): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 18, 2013. The stock’s 52-week high is $54.31, and its 52-week low is $40.51. Cramer had good things to say about Verizon, including its good yield, even though the stock has not really performed well so far this summer. The company’s deal with Vodafone (NASDAQ:VOD)– by which it bought out Vodafone’s 45 percent stake in Verizon Wireless– is expected to boost the company’s profitability as more customers switch from land lines to mobile devices.
Oasis Petroleum Inc. (NYSE:OAS): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on April 12, 2013. The stock’s 52-week high is $49.19, and its 52-week low is $28.15. Cramer was bullish about the oil company, which has performed very well over the course of the last month. Many analysts are also fans of the stock, which has a consensus buy rating with an average price target of over $50.
Pharmacyclics Inc. (NASDAQ:PCYC): Jim Cramer ranked this stock a Buy. The stock’s 52-week high is $136.59, and its 52-week low is $44.91. Cramer had a positive review of Pharmacyclics, a stock that he recommends despite it having soared by almost 130 percent this year. Cramer pointed to the potential of its new blood cancer drug, which not only has been effective in trials but also is powerful enough to be a treatment package all by itself, foregoing the need for an otherwise standard cocktail of drugs to be administered. One thing to note in looking at the company’s numbers, Cramer added, was that the company is in a revenue sharing agreement for the blood cancer drug.